金花三张牌免费版 - Official Release Repository: ACIP

ACIP description of work group activities for the Childhood and Adolescent Immunization Schedule (V体育平台登录)

ACIP Work Groups – October 8, 2025

Childhood and adolescent immunization schedule "Workgroup Terms of Reference"

ACIP Work Groups – October 8, 2025

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2025-26 Influenza Season

ACIP Recommendations – August 28, 2025

V体育官网入口 - Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025

ACIP Recommendations – August 28, 2025

V体育平台登录 - ACIP recommends routine annual influenza vaccination of all persons aged 6 months and older who do not have contraindications for the 2025-2026 season and recommends only single-dose formulations of annual influenza vaccines that are free of thimerosal as a preservative be used for children 18 years or younger, pregnant women, and all adults

ACIP – July 22, 2025

ACIP recommends adults 50 through 59 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine. CDC will publish Clinical Considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation.

ACIP – June 25, 2025

V体育平台登录 - ACIP recommends MenABCWY (Penmenvy GSK) vaccine, may be used for healthy persons aged 16–23 years when shared clinical decision-making favors administration of MenB vaccine and persons aged 10 years and over who are at increased risk for meningococcal disease when both MenACWY and MenB are indicated at the same visit

ACIP – June 25, 2025

ACIP recommends infants aged less than 8 months born during or entering their first RSV season who are not protected by maternal vaccination receive one dose of clesrovimab (Enflonsia, Merck)

ACIP – June 25, 2025

ACIP recommendations for use of Jynneos (smallpox/mpox vaccine, Bavarian Nordic A/S) for persons aged 18 years and older at risk for mpox during an mpox outbreak

ACIP Recommendations – June 19, 2025

ACIP approved Chikungunya recommendations at its April 15-16, 2025, meeting

ACIP – April 16, 2025

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025

ACIP Recommendations – January 16, 2025

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025

ACIP Recommendations – January 16, 2025

V体育官网入口 - ACIP recommends a single dose of PCV for all adults aged 50 years and older who are PCV-naïve or who have unknown vaccination history

ACIP Recommendations – January 9, 2025

ACIP recommends new dosing interval and schedule for the Bexsero MenB-4C vaccine

ACIP Recommendations – December 12, 2024

"V体育2025版" ACIP recommends use of additional doses of 2024–2025 COVID-19 vaccine for adults aged 65 Years and older and persons aged 6 Months and older with moderate or severe immunocompromise

ACIP Recommendations – December 12, 2024

"V体育2025版" Updated Recommendation for Universal Hepatitis B Vaccination in Adults Aged 19–59 Years — United States, 2024

ACIP – December 5, 2024

ACIP recommends 21-valent PCV (PCV21) as an option for adults aged 19 years and older who are currently recommended to receive PCV15 or PCV20 (V体育官网入口)

ACIP Recommendations – September 12, 2024

"VSports最新版本" ACIP recommends that Vaxelis [DTaP-IPV-Hib-HepB]) be included with monovalent PRP-OMP (Pedvax Hib)in the preferential recommendation for AI/AN infants based on the Hib component

ACIP Recommendations – September 12, 2024

ACIP recommends use of the 2024-25 COVID-19 vaccines for persons six months and older

ACIP Recommendations – September 10, 2024

ACIP Recommendations: Prevention and Control of Seasonal Influenza with Vaccines, US, 2024–25 Influenza Season

ACIP Recommendations – August 29, 2024

ACIP recommendations for the use of respiratory syncytial virus (RSV) vaccines in adults 60 years and older

ACIP – August 6, 2024

CDC approves ACIP recommendations for RSV for adults, DTaP-IPV-Hib-HepB (Vaxelis®️), COVID-19, Influenza, and Pneumococcal Vaccines

ACIP meeting – June 28, 2024

ACIP recommends use of an additional updated 2023–2024 COVID-19 vaccine dose for adults aged 65 Years and older

ACIP Recommendations – April 25, 2024

VSports在线直播 - ACIP recommendations for use of pentavalent meningococcal vaccine (Pfizer) for persons 10 years and older

ACIP Recommendations – April 18, 2024

VSports手机版 - CDC endorses ACIP recommendations for additional dose 2023-24 COVID-19 vaccine for adults ages 65 years and older and Chikungunya vaccine for travelers and lab workers

ACIP meeting – February 28, 2024

V体育官网 - Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024

ACIP – January 11, 2024

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024

ACIP – January 11, 2024

ACIP recommends Inactivated Polio Vaccine (IPV) for all adults 18 years and older known or suspected to be unvaccinated or incompletely vaccinated against polio

ACIP Recommendations – December 8, 2023

ACIP recommends use of Tick-Borne Encephalitis (TBE) vaccine for certain travelers and any laboratory workers who work with the virus

ACIP Recommendations – November 10, 2023

ACIP recommends use of updated COVID-19 vaccines for persons 6 months of age and older

ACIP Recommendations – October 10, 2023

ACIP recommends RSV vaccine (Abrysvo, Pfizer) for pregnant persons at 32–36 weeks' gestation using seasonal administration (September–January in most of the United States) to prevent RSV-associated lower respiratory infections in infants less than 6 months of age

ACIP Recommendations – October 6, 2023

ACIP recommendations on the use of PCV20 (Pfizer) for children (VSports app下载)

ACIP Recommendations – September 29, 2023

Recommendations for Prevention and Control of Influenza in Children, 2019–2020 - AAP Policy Statement

AAP Policy Statement – September 19, 2023

ACIP recommendations for the use of pneumococcal vaccines in adults 19 years of age and older (V体育官网入口)

ACIP Recommendations – September 8, 2023

ACIP recommendations on use of nirsevimab (Beyfortus, Sanofi) for infants aged less than 8 months born during or entering their first RSV season and for infants and children aged 8–19 months who are at increased risk of severe RSV disease entering their second RSV season.

ACIP Recommendations – August 25, 2023

Prevention and Control of Seasonal Influenza with Vaccines, 2023-24

ACIP Recommendations – August 25, 2023

ACIP recommendations on use of Respiratory Syncytial Virus (RSV) vaccines (Pfizer Abrysvo and GSK Arexvy) in older adults

ACIP Recommendations – July 21, 2023

ACIP interim recommendations for use of bivalent mRNA vaccines for persons aged 6 months – 5 years, adults 65 and older, and for those with immunocompromising conditions

ACIP Recommendations – June 16, 2023

Updated Recommendation from ACIP for Use of Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — U.S. April 2021 (V体育官网)

ACIP Recommendations – April 27, 2023

"V体育官网" ACIP recommends Priorix (GSK) as an additional option to prevent MMR according to existing vaccine recommendations and off-label uses, US, 2022

ACIP Recommendations – November 18, 2022

ACIP interim recommendations for the use of bivalent booster doses of COVID-19 vaccines, US October 2022

ACIP Recommendations – November 11, 2022

"VSports手机版" ACIP recommendation for the use of cholera (Vaxchora, Emergent Biosolutions) vaccine

ACIP Recommendations – September 30, 2022

ACIP recommends use of PCV15 as an option for pneumococcal vaccination for children under 19 years of age, using currently recommended PCV13 dosing and schedules (V体育官网入口)

ACIP Recommendations – September 16, 2022

Prevention and Control of Seasonal Influenza with Vaccines, 2022-23

ACIP Recommendations – August 26, 2022

"VSports app下载" ACIP interim recommendation for use of Novavax COVID-19 vaccine in adults 18 years and older, US, July 2022

ACIP – August 5, 2022

V体育官网 - ACIP interim recommendations for use of Moderna and Pfizer-BioNTech COVID-19 vaccines in children aged 6 Months–5 Years — US, June 2022

ACIP – June 28, 2022

ACIP recommendations for use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses, US, 2022

ACIP Recommendations – May 27, 2022

ACIP updates rabies vaccine recommendations - Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies, US, 2022

ACIP Recommendations – May 6, 2022

VSports最新版本 - ACIP recommends universal hepatitis B vaccination in adults aged 19-59 Years, US, 2022

ACIP Recommendations – April 1, 2022

ACIP Recommendation for use of Moderna COVID-19 Vaccine in Adults aged 18 years and older, considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines — US, February 2022

ACIP Recommendations – March 18, 2022

Use of Ebola Vaccine: Expansion of ACIP Recommendations to include two additional populations, US, 2021.

ACIP Recommendations – February 25, 2022

ACIP updates recommendations for adults on use of 15-Valent Pneumococcal Conjugate Vaccine (Vaxneuvance, Merck) PCV15 and 20-Valent Pneumococcal Conjugate Vaccine (Prevnar 20, Pfizer), US, 2022.

ACIP Recommendations – January 28, 2022

ACIP Recommendations for Use of Recombinant Zoster Vaccine (RZV, Shingrix, GSK) in Immunocompromised Adults aged 19 years and older, US, 2022.

ACIP Recommendations – January 21, 2022

V体育官网入口 - ACIP Updated Interim Recommendations for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine, US, December 2021.

ACIP Recommendations – January 21, 2022

ACIP Recommendations on Dengue Vaccine, US, 2021.

ACIP Recommendations – December 17, 2021

ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - US, 2021

ACIP Recommendations – November 5, 2021

ACIP Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines – US, 2021 (V体育安卓版)

ACIP Recommendations – October 29, 2021

Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021

ACIP Recommendations – September 21, 2021

Prevention and Control of Seasonal Influenza with Vaccines, 2021-22

ACIP Recommendations – August 27, 2021

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update ACIP, July 2021

ACIP Recommendations – August 13, 2021

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from ACIP - US, June 2021

ACIP Recommendations – July 6, 2021

ACIP Interim Recommendations for use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 years, US, May 2021

ACIP Recommendations – May 14, 2021

ACIP Interim Recommendation for Use of Janssen (Johnson and Johnson) COVID-19 Vaccine - U.S., February 2021

ACIP Recommendations – March 2, 2021

"VSports app下载" 2021 U.S. Recommended Immunization Schedules for Children and Adolescents Age 18 Years or Younger

ACIP/AAP/AAFP/ACOG Recommendations – February 12, 2021

2021 U.S. Recommended Immunization Schedule for Adults Aged 19 Years or Older

ACIP/AAFP/ACP/ACOG/ACNM – February 12, 2021

Vaccine Topics

General Topics

Patient Safety Honor Rolls

Our Affiliated Sites